[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100483469":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":54,"centralContacts":10,"locations":59,"responsibleParty":80,"collaborators":10,"id":82,"slug":83,"hasResults":84,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":10,"eligibilityCriteria":88,"healthyVolunteers":84,"sex":89,"minAge":90,"maxAge":10,"enrollmentInfo":91,"targetDuration":10,"studyType":94,"phases":10,"briefSummary":95,"conditions":96,"keywords":10,"overallStatus":61,"whyStopped":10,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":109},{"fullName":5,"class":6},"Mayo Clinic","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Observational (18F-TFB PET\u002FCT)",null,"Patients receive fluorine F18 tetrafluoroborate IV and undergo PET\u002FCT scan on study.",[13,14,15,16],"Procedure: Computed Tomography","Radiation: Fluorine F 18 Tetrafluoroborate","Procedure: Positron Emission Tomography","Other: Survey Administration",[18,32,40,50],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":23},"PROCEDURE","Computed Tomography","Undergo a PET\u002FCT scan",[9],[24,25,26,27,28,29,30,31],"CAT","CAT Scan","Computed Axial Tomography","Computerized Axial Tomography","Computerized Tomography","CT","CT Scan","tomography",{"type":33,"name":34,"description":35,"armGroupLabels":36,"otherNames":37},"RADIATION","Fluorine F 18 Tetrafluoroborate","Given IV",[9],[38,39],"18F-Tetrafluoroborate","18F-TFB",{"type":19,"name":41,"description":21,"armGroupLabels":42,"otherNames":43},"Positron Emission Tomography",[9],[44,45,46,47,48,49],"Medical Imaging, Positron Emission Tomography","PET","PET Scan","Positron Emission Tomography Scan","Positron-Emission Tomography","proton magnetic resonance spectroscopic imaging",{"type":6,"name":51,"description":52,"armGroupLabels":53,"otherNames":10},"Survey Administration","Ancillary studies",[9],[55],{"name":56,"affiliation":57,"role":58},"Stephen M. Broski, M.D.","Mayo Clinic in Rochester","PRINCIPAL_INVESTIGATOR",[60],{"facility":57,"status":61,"city":62,"state":63,"zip":64,"country":65,"countryCode":66,"cosmosGeoPoint":67,"geoPoint":72,"contacts":73},"RECRUITING","Rochester","Minnesota","55905","United States","US",{"type":68,"coordinates":69},"Point",[70,71],-92.4699,44.02163,{"lat":71,"lon":70},[74,79],{"name":75,"role":76,"phone":77,"phoneExt":10,"email":78},"Clinical Trials Referral Office","CONTACT","855-776-0015","mayocliniccancerstudies@mayo.edu",{"name":56,"role":58,"phone":10,"phoneExt":10,"email":10},{"type":81,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100483469","evaluation-of-18f-tfb-petct-scan-in-patients-with-differentiated-thyroid-cancer-100483469",false,"NCT05575440","Evaluation of 18F-TFB PET\u002FCT Scan in Patients With Differentiated Thyroid Cancer","Evaluation of F-18 Tetrafluoroborate (18F-TFB) PET\u002FCT in Patients With Differentiated Thyroid Cancer","Inclusion Criteria:\n\n* Subject has biopsy-proven papillary or follicular thyroid cancer\n* Subject is clinically indicated for 123I-SPECT\u002FCT total body iodine (TBI) scan\n* Subject agrees to undergo 18F-TFB PET\u002FCT scan following TBI scan\n* Karnofsky performance status of \\>= 50 (or Eastern Cooperative Oncology Group \\[ECOG\\]\u002FWorld Health Organization \\[WHO\\] equivalent)\n* Subject is able to be scanned - able to lie still on SPECT\u002FCT and PET\u002FCT scanner table for up to 65 minutes (min)\n* Age 18 or older\n* Ability to understand a written informed consent document, and the willingness to sign it\n* Subject is not pregnant\n\nExclusion Criteria:\n\n* Contrast-enhanced CT within 4 last weeks\n* Amiodarone within last 4 months\n* Ingested iodine, kelp tablets, Lugols iodine, or potassium iodide (SSKI) within 2 weeks\n* Unable to lie flat, still or tolerate a PET scan\n* Applied betadine, iodoform, or quick tanning products to skin within last two weeks\n* If using medication withdrawal for stimulation, then exclude if thyroid stimulating hormone (TSH) level \\\u003C 25\n* Taken anti-thyroid medication within 1 week\n* Subject is breastfeeding\n* Positive pregnancy test","ALL","18 Years",{"count":92,"type":93},24,"ESTIMATED","OBSERVATIONAL","This phase II study evaluates F-18 tetrafluoroborate (18F-TFB) PET\u002FCT scan in patients with differentiated thyroid cancer. Diagnostic imaging is necessary for planning treatment, monitoring therapy response, and identifying sites of recurrent or metastatic disease in differentiated thyroid cancer. 18F-TFB PET\u002FCT may accurately detect recurrent and metastatic thyroid cancer lesions, with the potential to provide information for patient management that is better than the current standard of care imaging practices.",[97,98,99],"Differentiated Thyroid Gland Carcinoma","Thyroid Gland Follicular Carcinoma","Thyroid Gland Papillary Carcinoma","2026-02-24",{"date":102,"type":103},"2026-02-27","ACTUAL",{"date":105,"type":103},"2022-04-22",{"date":107,"type":93},"2028-05-01",{"name":5,"class":6},1]